Alirocumab, evinacumab, and atorvastatin triple therapy regresses plaque lesions and improves lesion composition in mice

Atherosclerosis-related CVD causes nearly 20 million deaths annually. Most patients are treated after plaques develop, so therapies must regress existing lesions. Current therapies reduce plaque volume, but targeting all apoB-containing lipoproteins with intensive combinations that include alirocuma...

Disgrifiad llawn

Wedi'i Gadw mewn:
Manylion Llyfryddiaeth
Cyhoeddwyd yn:J Lipid Res
Prif Awduron: Pouwer, Marianne G., Pieterman, Elsbet J., Worms, Nicole, Keijzer, Nanda, Jukema, J. Wouter, Gromada, Jesper, Gusarova, Viktoria, Princen, Hans M. G.
Fformat: Artigo
Iaith:Inglês
Cyhoeddwyd: The American Society for Biochemistry and Molecular Biology 2020
Pynciau:
Research Articles
Mynediad Ar-lein:https://ncbi.nlm.nih.gov/pmc/articles/PMC7053846/
https://ncbi.nlm.nih.gov/pubmed/31843957
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1194/jlr.RA119000419
Tagiau: Ychwanegu Tag
Dim Tagiau, Byddwch y cyntaf i dagio'r cofnod hwn!

Eitemau Tebyg